High MAL2 expression predicts shorter survival in women with triple‑negative breast cancer

• Jędrzej Borowczak ^[2] ; Marek Zdrenka ^[2] ; Krzysztof Szczerbowski ^[2] ; Mateusz Maniewski ^[2] ; Hanna Andrusewicz ^[2] ; Joanna Łysik Miśkurka ^[2] ; Łukasz Szylberg ^[2] ; Weronika Socha ^[1] ; Karol Gostomczyk ^[1] ; Magdalena Bodnar ^[1] ; Tomasz Nowikiewicz ^[3]
  1. [1] Nicolaus Copernicus University

     Nicolaus Copernicus University

     Toruń, Polonia

     
  2. [2] Department of Tumor Pathology and Pathomorphology, Oncology Centre, Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland
  3. [3] Clinical Department of Breast Cancer and Reconstructive Surgery, Oncology Center, Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 10, 2024, págs. 2549-2558
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction Due to its lack of conventional surface receptors, triple-negative breast cancer (TNBC) is inherently resistant to most targeted therapies. MAL2 overexpression prompts endocytosis, conferring resistance to novel therapeutics. This study explores the role of MAL2 and PD-L1 in TNBC patients’ prognosis.

    Methods We performed immunohistochemical analysis on 111 TNBC samples collected from 76 patients and evaluated the expression of MAL2 and PD-1. We expanded the study by including The Cancer Genome Atlas (TCGA) cohort.

    Results MAL2 expression did not correlate with stage, grade, tumor size, lymph node invasion, metastasis, and PD-1 expression. Patients with high MAL2 had significantly lower 5-year survival rates (71.33% vs. 89.59%, p = 0.0224). In the tissue microarray cohort (TMA), node invasions, size, recurrence, and low MAL2 (HR 0.29 [CI 95% 0.087–0.95]; p < 0.05) predicted longer patients’ survival. In the TCGA cohort, patients with low MAL2 had significantly longer overall survival and disease-specific survival than patients with high MAL2. Older age and high MAL2 expression were the only independent predictors of shorter patient survival in the BRCA TCGA cohort.

    Conclusion High MAL2 predicts unfavorable prognosis in triple-negative breast cancer, and its expression is independent of PD-1 levels and clinicopathological features of TNBC.